eligibility_summary
Eligible: 18–75 with R/R CD19+ B‑cell lymphoma (DLBCL/TFL/PMBCL, MCL refractory/intolerant to BTKi, indolent after ≥3 lines), prior CD20 mAb + anthracycline, ≥1 measurable lesion, ECOG 0–2, adequate organs, expected survival ≥12 wks, prior SCT/failed CAR‑T allowed, ≥3 wks since last therapy, two COVID‑negative tests, women: negative pregnancy test + contraception. Exclude: product allergy, other cancers, GVHD, recent gene therapy, active infection, HBV/HCV/HIV/syphilis, NYHA III–IV, unresolved ≥2 AEs, CNS disease/lymphoma, prior anti‑CD19, breastfeeding, other risks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: anti-CD19 IL-10/IL-15 CAR-NK cells (biologic, genetically engineered cellular therapy). Cord blood–derived natural killer (NK) cells are lentivirally transduced to express a CD19-directed chimeric antigen receptor and IL-10/IL-15. Mechanism of action: The CAR confers antigen-specific recognition and cytotoxic killing of CD19+ B cells. IL-15 provides autocrine support to enhance NK activation, proliferation, and persistence (JAK/STAT signaling). IL-10 is an immunoregulatory cytokine intended to temper excessive inflammation and potentially reduce toxicity while modulating the tumor microenvironment. Targets: CD19 on malignant B cells in B-cell non-Hodgkin lymphoma, pathways include CAR-mediated NK cytotoxicity and IL-15–driven survival signaling.